Osiris to Present at the 26th European Wound Management Association Conference
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
The Conference of the European Wound Management Association (EWMA), the 10th Deutscher Wound Congress (Wundkongress) and the 2nd Wound D·A·CH (WundD·A·CH) conference have joined forces and are offering participants a comprehensive programme on May 11-13, 2016 in Bremen, Germany. With over 5,000 participants, the overall theme of the conference is “Patients – Wounds – Rights”. With this theme, the conference wishes to highlight the continuous need to ensure that wound management is offered with a holistic approach to the patient. One of the primary preconditions for achieving this is the involvement of interdisciplinary teams in wound management. As an association representing many disciplines, specialties and countries, it lies in the nature of EWMA to open up for widely different interests and perspectives on best practice wound care.
Dr. Daniel Davis, DPM, APMA President, will present at a symposium partnered with Osiris Therapeutics, Inc., and chaired by Dr. Matthew Young, Consultant Diabetologist (Edinburgh) on the Next Generation of Wound Care: Introducing Viable Cryopreserved Placental Membrane. Dr. Alla Danilkovitch, Chief Scientific Officer will summarize the science and clinical evidence for Osiris’ viable placental membrane products. In addition, Dr. Davis will cover the recent Grafix® complex wound study, the first prospective study on skin substitutes that focuses on patients with wounds that have exposed bone and tendon. He will also review several complex clinical cases that Osiris’ Grafix products have helped close, including a wound that had been present for two years prior to treatment with Grafix.
“Osiris plans to continue growth internationally and we are proud to share our viable allograft knowledge at this International conference,” said Dwayne Montgomery, President and CEO of Osiris. “We look forward to presenting to not only physicians, but also surgeons, nurses, podiatrists, tissue viability specialists and regulators about the exceptional clinical and economic benefits our products offer.”
Scientific and Clinical Posters
- Antimicrobial Peptides in Human Cryopreserved Viable Amniotic Membrane Inhibit Bacterial Growth
- Understanding Placental Products: Impact of Commercial Preservation Methods on Anti-Inflammatory and Angiogenic Properties
- Unique Feature of Living Amniotic Tissue: Cell Protection from Oxidant-Induced Damage via the Release of Anti-oxidant Mediators
- A Comparison Study between Viable and Devitalized Cryopreserved Human Amniotic Membrane
- Characterization of Novel Human Mesenchymal Stem Cell-Containing Skin Substitute for the Treatment of Wounds
- Treatment of Challenging Lower Extremity Wounds with Bone and Tendon Exposure: Using a Uniquely Viable and Intact Cryopreserved Human Placental Membrane Graft for Closure
- Wound Closure of Chronic Foot Ulcers using Cryopreserved Human Amniotic Membrane (cHAM)
- The Use of an Intact Viable Cryopreserved Placental Membrane (vCPM) in the Closure of Chronic Wounds
- Challenging Lower Limb Ulcerations in Patients with Impaired Tissue Perfusion: Application of a Viable Intact Cryopreserved Human Amniotic Membrane to Achieve Wound Closure
- Expedient Wound Closure Utilizing Viable Placental Tissue in Serious Limb Threatening Infection: A Case Study
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4®, a viable bone matrix, Cartiform®, a viable osteochondral allograft, Grafix, a cryopreserved placental membrane, TruSkin™, a viable human skin allograft and Stravix™, a durable placental allograft.
Osiris, Grafix and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc. BIO4 is a registered trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company's website, www.Osiris.com. (OSIR-G)
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO4, Cartiform, TruSkin and Stravix); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; results of our scientific research; the timing of our amended 2015 filings; and the engagement of our successor accounting firm. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
For additional information, please contact:
Osiris Therapeutics, Inc.
Amanda Badillo, 443-545-1834
For International inquiries, please contact:
Osiris Therapeutics, Inc.
Paul Saunders, +44 771 388 5257
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Theorem Solutions: Democratising Augmented, Mixed and Virtual Reality24.10.2017 10:00 | Pressemelding
Theorem Solutions of Tamworth, UK, have launched a ‘Multi-Device’ Visualization Experience App for Augmented (AR), Mixed (MR) and Virtual Reality (VR) devices and markets. The Visualization Experience app forms part of Theorem’s ‘Digital Realities’ product family, and has been specifically developed for users to engage and interact with their Engineering and Manufacturing data. It is one of the first to offer a single solution for all three different technologies in a single application. Supported devices are: Augmented Reality - Windows 10 and Android Tablets and Phones Mixed Reality – Microsoft HoloLens Virtual Reality - HTC Vive and Oculus Rift Being Multi-Device, the application allows users to use the same data, in the same visualization application, on ALL of the different
Sigma Systems CTO Catherine Michel to Speak at Women in Communications Event24.10.2017 09:00 | Pressemelding
Sigma Systems, the global leader in catalog-driven software, has confirmed today that its Chief Technology Officer, Catherine Michel, will be speaking at Light Reading’s Women in Comms luncheon to be held November 1st in London. The event will take place during Light Reading’s OSS in the Era of SDN and NFV conference. Speakers include the editors of Light Reading and analysts of Heavy Reading, alongside industry guest speakers including Sigma’s Catherine Michel. This event brings together leading women in communications and their male allies to discuss everything related to the state of the industry today, including why diversity in the workplace matters, and why companies should care about the disparity in representation and pay of female employees. Earlier this year, Catherine was named to the top 50 Women to Watch 2017 and the Power 100 by Global Telecoms Business - the o
GSMA Mobile IoT Initiative Helping Operators Target European Connected Energy Market Worth USD$26 Billion24.10.2017 08:00 | Pressemelding
The GSMA today announced that mobile operators deploying new Mobile IoT networks will be able to benefit from the European connected energy market estimated to be worth USD$26 billion by 20261. Data shared by analyst house Machina Research highlights the huge growth opportunity in the emerging connected energy market that could connect approximately 158 million new smart meters on LPWA networks across Europe. The total number of connections in Europe could be further increased if the 60 million cellular connections are also included with LPWA. “The Internet of Things is fundamentally disrupting the smart utility market by providing ubiquitous connectivity and real-time, actionable data. Mobile IoT networks will take this further by offering energy providers a cost-effective solution to connect millions of smart meters,” said Alex Sinclair, Chief Technology Officer, GSMA. “There is a
RevolutionAir: Philips Launches a Brand-New Wireless SpeechMike Premium Air24.10.2017 07:02 | Pressemelding
Speech Processing Solutions, the world’s number one in professional dictation, has just released its latest innovation, the wireless SpeechMike Premium Air dictation microphone. For the first time in history, the new device offers not only outstanding audio recording quality, enabling exceptional speech recognition results, best in class quality and ergonomics, but also a wireless dictation microphone, based on 100% lossless speech technology. The dictation microphone allows users to quickly turn their voice into text, saving them time and making them more effective at their core profession. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005093/en/ Philips SpeechMike Premium Air (Photo: Business Wire) Lossless speech technology The high-quality device deliver
Philip Morris International Recognized for Environmental Leadership on CDP’s A List for Climate and Water24.10.2017 07:00 | Pressemelding
Philip Morris International Inc. (“PMI”) (NYSE/Euronext Paris: PM) today was again recognized as a global leader for environmental action in the annual CDP rankings. For the fourth year in a row, PMI is on the CDP Climate A List for taking comprehensive action on climate change and for its transparent disclosure process. In addition, PMI achieved A List status for CDP Water, recognizing the company’s water stewardship initiatives. PMI is one of only 25 companies that scored an A for both climate and water, placing the company in the top 1% of corporations known as the “A Listers” for both schemes. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005711/en/ CDP, formerly known as the Carbon Disclosure Project, is the leading international not-for-profit organization independently assessing the environmental efforts of t
QVC Makes the Leap into Ultra HD in Germany with SES Video24.10.2017 06:50 | Pressemelding
QVC will bring an enhanced TV experience to its viewers with the launch of its Ultra HD channel in Germany, the seventh channel in ultra-high definition in the country, via SES’s prime orbital slot 19.2 degrees East. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005870/en/ QVC Makes the Leap into Ultra HD in Germany with SES Video (Photo: Business Wire) Under the ten-year agreement announced by SES, QVC will utilize additional capacity for its upgrade to Ultra HD and rely on SES’s wholly-owned subsidiary MX1 for encoding in HEVC format and uplink services. QVC is also renewing capacity for distribution of the channel in Standard and High Definition. “As we carry the largest line-up of HD and UHD channels worldwide, it is part of our DNA to help our customers bring the best pos
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom